Esperion Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Esperion Therapeutics, Inc. (ESPR), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ESPR insiders buying or selling?
In the last 12 months, Esperion Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 11 sales ($578.9K) — net selling of $578.9K. Since January 2018, Trabud has recorded 112 Form 4 filings for ESPR: 36 buys ($56.5M) and 76 sells ($12.0M).
Source: SEC EDGAR Form 4
Key Statistics (January 2018 – Jun 18, 2026)
Total Form 4 filings
112
SEC EDGAR
Insider filers
13
Insider buys (36)
$56.5M
Insider sells (76)
$12.0M
Insider sentiment
Net buyingNet insider flow of $44.4M in net buying since January 2018, and $578.9K in net selling over the last 12 months.
Recent ESPR insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Benjamin Looker | Chief Legal Officer | Sale | 11.8K | $3.16 | $37.3K | SEC ↗ |
| Jun 18, 2026 | Sheldon L. Koenig | President and CEO | Sale | 53.6K | $3.16 | $169.1K | SEC ↗ |
| Jun 18, 2026 | Benjamin Halladay | Chief Financial Officer | Sale | 10.8K | $3.16 | $34.0K | SEC ↗ |
| Mar 18, 2026 | Benjamin Looker | Chief Legal Officer | Sale | 5.7K | $2.70 | $15.4K | SEC ↗ |
| Mar 18, 2026 | Sheldon L. Koenig | President and CEO | Sale | 25.6K | $2.72 | $69.5K | SEC ↗ |
| Mar 18, 2026 | Benjamin Halladay | Chief Financial Officer | Sale | 6.4K | $2.71 | $17.4K | SEC ↗ |
| Jan 21, 2026 | Benjamin Looker | General Counsel | Sale | 1.7K | $2.88 | $4.9K | SEC ↗ |
| Dec 18, 2025 | Sheldon L. Koenig | President and CEO | Sale | 48.2K | $3.67 | $177.2K | SEC ↗ |
| Dec 18, 2025 | Benjamin Halladay | Chief Financial Officer | Sale | 7.3K | $3.67 | $26.9K | SEC ↗ |
| Dec 18, 2025 | Benjamin Looker | General Counsel | Sale | 6.5K | $3.67 | $23.9K | SEC ↗ |
| Oct 20, 2025 | Benjamin Looker | General Counsel | Sale | 1.2K | $2.62 | $3.3K | SEC ↗ |
| Sep 18, 2025 | Benjamin Looker | General Counsel | Sale | 6.3K | $2.80 | $17.6K | SEC ↗ |
| Sep 18, 2025 | Sheldon L. Koenig | President and CEO | Sale | 28.4K | $2.79 | $79.3K | SEC ↗ |
| Sep 18, 2025 | Benjamin Halladay | Chief Financial Officer | Sale | 7.0K | $2.81 | $19.8K | SEC ↗ |
| Jul 18, 2025 | Benjamin Looker | General Counsel | Sale | 1.3K | $1.13 | $1.5K | SEC ↗ |
| Jul 18, 2025 | Benjamin Halladay | Chief Financial Officer | Sale | 11 | $1.12 | $12.27 | SEC ↗ |
| Jun 18, 2025 | Benjamin Looker | General Counsel | Sale | 6.4K | $1.15 | $7.4K | SEC ↗ |
| Jun 18, 2025 | Sheldon L. Koenig | President and CEO | Sale | 30.5K | $1.11 | $33.8K | SEC ↗ |
| Jun 18, 2025 | Benjamin Halladay | Chief Financial Officer | Sale | 7.2K | $1.15 | $8.3K | SEC ↗ |
| Apr 21, 2025 | Eric Warren | Chief Commercial Officer | Sale | 108 | $0.98 | $105.62 | SEC ↗ |
| Apr 21, 2025 | Benjamin Halladay | Chief Financial Officer | Sale | 8 | $0.96 | $7.71 | SEC ↗ |
| Mar 19, 2025 | Benjamin Halladay | Chief Financial Officer | Sale | 3.5K | $1.48 | $5.2K | SEC ↗ |
| Mar 19, 2025 | Eric Warren | Chief Commercial Officer | Sale | 2.4K | $1.49 | $3.6K | SEC ↗ |
| Mar 19, 2025 | Sheldon L. Koenig | President and CEO | Sale | 13.0K | $1.50 | $19.6K | SEC ↗ |
| Feb 20, 2025 | Eric Warren | Chief Commercial Officer | Sale | 239 | $1.87 | $446.45 | SEC ↗ |
Showing the 25 most recent of 112 Form 4 filings for Esperion Therapeutics, Inc..
Most active ESPR insiders
- Eric Warren27 filings
- V N Biotech Target19 filings
- Sheldon L. Koenig15 filings
- Benjamin Halladay11 filings
- Benjamin Looker10 filings
Ask anything about ESPR insider activity
Use Trabud's AI agent to query Esperion Therapeutics, Inc.'s Form 4 history in plain English — "Show me ESPR CEO purchases this year" or compare it against any other ticker.
Open the AI agentESPR insider trading FAQ
Are Esperion Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Esperion Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 11 sales ($578.9K) — net selling of $578.9K. Since January 2018, Trabud has recorded 112 Form 4 filings for ESPR: 36 buys ($56.5M) and 76 sells ($12.0M). Over the full record that is net buying of $44.4M.
How many insiders trade ESPR stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Esperion Therapeutics, Inc.. The most recent filing was accepted on Jun 18, 2026.
Where does Trabud get ESPR insider trading data?
All ESPR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.